<DOC>
	<DOC>NCT02632292</DOC>
	<brief_summary>Prospective, randomized, controlled, multicenter, open-label study to compare everolimus-eluting bioresorbable vascular scaffolds to everolimus-eluting stents in patients with diabetes mellitus.</brief_summary>
	<brief_title>EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Clinical inclusion criteria: Age ≥18 years DM type I or II based on the definitions of the American Diabetes Association Angiographically proven CAD Angina pectoris, equivalent symptoms, and/or positive stress test, and/or instantaneous flow reserve ≤0.86, and/or fractional flow reserve ≤0.80 Negative pregnancy test in women with childbearing potential Angiographic inclusion criteria: Denovo lesion in at least one native coronary artery Luminal diameter reduction 5099% assessed by visual estimation Target reference vessel diameter 2.5 4.0 mm Clinical exclusion criteria: Limited longterm prognosis with a lifeexpectancy &lt;12 months Contraindications to antiplatelet therapy Known allergy against cobalt chrome, everolimus, or polylactic acid Angiographic exclusion criteria: Target lesion located in the left main trunk Severe calcification of the target lesion as determined by angiography Instent restenosis Bifurcation lesion with planned twostent strategy Chronic total occlusion Indication for CABG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>